Results 181 to 190 of about 19,808 (220)

Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies

Bioconjugate Chemistry, 2019
Radioligand therapy (RLT) relies on the use of pharmacophores to selectively deliver ionization energy to cancers to exert its tumoricidal effects. Cancer cells that are not directly targeted by a radioconjugate remain susceptible to RLT because of the crossfire effect. This is significant given the inter- and intra-heterogeneity of tumors.
Joseph Lau, Orit Jacobson, Gang Niu, Kuo-Shyan Lin, François Bénard, Xiaoyuan Chen   +5 more
openaire   +2 more sources

Radioligand-Guided Radiation Therapy Planning

International Journal of Radiation Oncology*Biology*Physics, 2022
openaire   +2 more sources

[PSMA-targeted radioligand therapy in prostate cancer].

Der Urologe. Ausg. A, 2017
Radioligand therapy (RLT) directed against prostate-specific membrane antigen (PSMA) enables tumor-specific treatment directed against PSMA-overexpressing prostate cancer cells. Several PSMA ligands such as PSMA-617 or PSMA-I&T have been developed that can be labeled with β‑radiating lutetium-177.
M M, Heck, M, Retz, R, Tauber, K, Knorr, C, Kratochwil, M, Eiber   +5 more
openaire   +1 more source

PSMA Radioligand Therapy in Advanced Age

Clinical Nuclear Medicine
Purpose: With increasing life expectancy, the number of older patients with metastatic castration-resistant prostate cancer (mCRPC) continues to rise, but this group is currently underrepresented in clinical trials. This study aims to assess the efficacy and safety of prostate-specific membrane antigen (PSMA) targeted ...
Moritz B. Bastian, Benedikt Wörl, Arne Blickle, Caroline Burgard, Tilman Speicher, Joel Wessendorf, Mark Bartholomä, Andrea Schaefer-Schuler, Stephan Maus, Samer Ezziddin, Florian Rosar   +10 more
openaire   +2 more sources

Prostate Cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals.

PET clinics
Prostate cancer is the most common malignancy in men worldwide, with an estimated 174,650 new cases per year in the United States, and the second cancer-related cause of death, after lung cancer, with 31,620 deaths per year. While the 5 year survival rate for prostate cancer in patients without metastatic spread is nearly 100%, those with distant ...
Yaniv, Yechiel, Alexandre, Chicheportiche, Zohar, Keidar, Simona, Ben-Haim   +3 more
openaire   +1 more source

Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians

Ca-A Cancer Journal for Clinicians, 2022
William A Hal, X Allen Li, Daniel A Low
exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Victoria Metaxa, Elie Azoulay   +2 more
exaly  

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Prostate Cancer Radioligand Therapy

PET Clinics
Yaniv Yechiel, Alexandre Chicheportiche, Zohar Keidar, Simona Ben-Haim   +3 more
openaire   +1 more source

Radioligand Therapy in Lymphoma

PET Clinics
Ludmila Santiago Almeida, Roberto C. Delgado Bolton, Victor Cabral Heringer, Samuel de Souza Medina, Elba Etchebehere   +4 more
openaire   +1 more source